An observational study in Endometriosis Pelvic, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-15.
Sponsored by University Hospital, Strasbourg, France · Observational
Schwannomas are mainly benign tumors, which develop mainly in the skull or in the cervical region. Retroperitoneal location is rare, since it represents between 0.5 and 5% of scwhanomas. The malignant retroperitoneal form is, however, more common than in other locations.
Retroperitoneal schwannoma is often discovered during the exploration of unexplained lumbo-pelvic pain, or in the face of compression of nearby organs. Abdominopelvic CT and magnetic resonance imaging are essential to characterize the mass and verify its extension. The precise diagnosis is based on the pathological examination of the part, and complete surgical excision is the standard treatment.
Acquiring the surgical techniques and skills necessary to carry out these types of procedures is essential to providing optimal patient care.
82 studies on the registry are indexed under Neurilemmoma; 21 are open to participants now.
This study's planned enrollment of 1 is below the median of 63 across 30 observational studies indexed under Neurilemmoma.
Browse Neurilemmoma studies →University Hospital, Strasbourg, France is the lead sponsor of 966 studies on the registry; 342 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
laparoscopic removal of a retroperitoneal pelvic schwannoma
The aim of this research is to train surgeons to perform laparoscopic removal of a retroperitoneal pelvic schwanoma
Time frame: Through study completion, an average of 1 month
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Strasbourg, France